Urokinase is a protein that has many functions. It is a serine protease and is a plasminogen activator. McFarlane and Pilling discovered this enzyme in 1947. It is essential for the activation of plasminogen, a type of protein that helps to prevent the formation of blood clots. During the 1940s, it was discovered in the body.
Although rare, urokinase can lead to life-threatening bleeding. It may cause slurred speech and a need for CPR. It may also lead to brain tumors and aneurysms. Some other possible complications of this medication include a stroke, cardiovascular arrest, and bleeding disorders. In rare instances, it may cause a life-threatening reaction. Some people should not use urokinase unless it is prescribed by a healthcare professional.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4151
Global Urokinase Market Drivers
The growing prevalence of pulmonary embolism globally is driving demand for blood clot busting agents. For instance, according to National Library of Health in 2018, pulmonary embolism have high prevalence globally with 10 million cases per year. Moreover, increasing usage of urokinase in the treatment of cardiovascular disease is again fostering demand for blood clot busting agents such as urokinase. For instance, in June 2020, Hospital of Zhenghou University started clinical trial on the treatment of minor heart stroke with urokinase thrombolysis, which is expected to complete in 2021. All these factors are projected to drive growth of the global urokinase market over the forecast period.
Global Urokinase Market COVID-19 Impact Analysis
Since the outbreak of COVID-19 pandemic from past year, each and every market and industry around the globe is affected in a negative way. According to American society of Hematology July 2020, 15-20% of patients suffering from acute pulmonary embolism and deep vein thrombosis require mechanical ventilation and blood clot busting agents after getting infected by COVID-19 infection. Moreover, According to World Health Organization 2019, it is observed that COVID-19 infection leads to formation of blood clots in patients, thus there is need of blood clot busting agents, when mechanical ventilators are in shortage due to increase in patient population infected by COVID-19 infection.
Global Urokinase Market Restraints
Urokinase is contraindicated in cancer patients, as urokinase elevates plasminogen activation systems, which lead to tissue invasion leading towards metastasis and causing cancer growth. Additionally, urokinase is also contraindicated in patients suffering from brain tumor and high blood pressure. These factors are projected to hinder growth of the global urokinase market.
Global Urokinase Market Regional Analysis
On basis of region global urokinase market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. High prevalence of pulmonary embolism and deep vein thrombosis in elder population in North America is expected to foster market growth. For instance, according to the National Library of Medicine report 2018, 600,000 cases of deep vein thrombosis are recorded per year with 100,000 deaths in the U.S. Thus, growing prevalence of deep vein thrombosis and pulmonary embolism are propeling demand for blood clot busters in the region. For instance, in 2018, Microbix Biosystem Inc, a biologics product manufacturer, entered into an agreement with Toreya Partners LLC for re-launch of kinlytics (urokinase) a clot busting drug in the U.S. market.
In Europe, pharmaceutical companies are focusing on product approvals in field of global urokinase market to strengthen their market share in the region. For instance, in 2019 Syner Medica LTD received approval for marketing of syner-kinase (urokinase) in the U.K. by European Medical Agency.
Global Urokinase Market Key Players
Key players operating in the global urokinase market include Jiangsu Aidea Pharmaceutical Co Ltd, Jiangxi Haoran Bio-Pharma Co., Ltd, Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, Microbix Biosystems Inc, Syner Medica LTD, ImaRx Therapeutics, Inc, and Wilex AG.
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4151
Market Taxonomy:
On the basis of distribution channel, the global urokinase market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of Formulation, the global urokinase market is segmented into:
- Urokinase Solution
- Urokinase Powder
On the basis of region, the global urokinase market is segmented into:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Direct Buy This Premium Research Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4151
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Urokinase Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Urokinase Industry Impact
Chapter 2 Global Urokinase Competition by Types, Applications, and Top Regions and Countries
2.1 Global Urokinase (Volume and Value) by Type
2.3 Global Urokinase (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Urokinase Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Urokinase Market Analysis
Chapter 6 East Asia Urokinase Market Analysis
Chapter 7 Europe Urokinase Market Analysis
Chapter 8 South Asia Urokinase Market Analysis
Chapter 9 Southeast Asia Urokinase Market Analysis
Chapter 10 Middle East Urokinase Market Analysis
Chapter 11 Africa Urokinase Market Analysis
Chapter 12 Oceania Urokinase Market Analysis
Chapter 13 South America Urokinase Market Analysis
Chapter 14 Company Profiles and Key Figures in Urokinase Business
Chapter 15 Global Urokinase Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
About US
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com